Voyageur Pharmaceuticals Ltd. Share Price OTC Markets
Stocks
VYYRF
CA92918C1014
Pharmaceuticals
OTC Markets Traded|
Market Closed -
OTC Markets
08:01:17 19/08/2026 pm IST
|
5-day change | 1st Jan Change | ||
| 0.1200 USD | 0.00% |
|
0.00% | -7.76% |
| Market Cap | 3.51Cr 2.55Cr 2.18Cr 2.04Cr 1.87Cr 243.79Cr 3.55Cr 24Cr 9.41Cr 122.47Cr 9.57Cr 9.36Cr 405.06Cr | P/E 2024 |
-5.24x | P/E 2025 | -7.5x |
|---|---|---|---|---|---|
| Enterprise Value | 3.49Cr 2.53Cr 2.17Cr 2.03Cr 1.86Cr 242.18Cr 3.53Cr 24Cr 9.35Cr 121.66Cr 9.5Cr 9.3Cr 402.4Cr | EV / Sales 2024 |
-
| EV / Sales 2025 | 2,42,35,81,172x |
| Free-Float |
93.07% | Yield 2024 * |
-
| Yield 2025 | - |
| Current month | +25.00% | ||
| 1 month | +9.09% | ||
| 3 months | +99.34% | ||
| 6 months | +9.09% | ||
| Current year | -7.76% |
| 1 week | 0.12 | 0.12 | |
| 1 month | 0.1 | 0.13 | |
| Current year | 0.01 | 0.2 | |
| 1 year | 0 | 0.2 | |
| 3 years | 0 | 0.25 | |
| 5 years | 0 | 0.25 | |
| 10 years | 0 | 0.25 |
| Manager | Title | Age | Since |
|---|---|---|---|
Brent Willis
CEO | Chief Executive Officer | - | 01/07/2019 |
| Director of Finance/CFO | - | 17/08/2022 | |
Iryna Saranchova
CTO | Chief Tech/Sci/R&D Officer | - | 17/09/2024 |
| Director | Title | Age | Since |
|---|---|---|---|
Brent Willis
BRD | Director/Board Member | - | 06/12/2017 |
Brad Willis
BRD | Director/Board Member | - | 01/07/2019 |
Eric Pommer
CHM | Chairman | - | 30/04/2025 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
| 0.00% | 0.00% | - | - | 2.55Cr | ||
| +0.88% | +6.38% | +76.86% | +128.23% | 1,11900Cr | ||
| +1.07% | +3.80% | +51.03% | +61.48% | 65TCr | ||
| +1.20% | +6.21% | +26.47% | +76.45% | 47TCr | ||
| +1.02% | +5.77% | +43.09% | +47.70% | 37TCr | ||
| +0.85% | +4.07% | +23.88% | +41.58% | 30TCr | ||
| +1.26% | +6.81% | +1.59% | +14.67% | 26TCr | ||
| +1.88% | +5.81% | +48.54% | +68.52% | 24TCr | ||
| +1.59% | +2.09% | -15.52% | -52.29% | 21TCr | ||
| +1.87% | +5.61% | +25.81% | +92.42% | 18TCr | ||
| Average | +1.16% | +4.97% | +31.31% | +53.20% | 42.22TCr | |
| Weighted average by Cap. | +1.14% | +5.09% | +44.31% | +72.55% |
| 2024 | 2025 | |
|---|---|---|
| Net sales | - | 0.01 0.01 0.01 0.01 0.01 0.81 0.01 0.08 0.03 0.41 0.03 0.03 1.35 |
| Net income | -17.07L -12.4L -10.62L -10L -9L -12Cr -17.3L -1.17Cr -45.79L -5.96Cr -46.56L -45.54L -20Cr | -35.33L -25.66L -21.98L -20.56L -18.82L -25Cr -35.79L -2.43Cr -94.74L -12Cr -96.33L -94.24L -41Cr |
| Net Debt | -1L -81.8T -70.07T -65.56T -60.02T -78.27L -1L -8L -3L -39.32L -3L -3L -1.3Cr | -2L -2L -1L -1L -1L -1.6Cr -2L -15.86L -6L -80.48L -6L -6L -2.66Cr |
Employees
-
Sector
Pharmaceuticals
| Date | Price | Change | Volume |
|---|---|---|---|
| 19/26/19 | $0.1200 | 0.00% | 1,00,000 |
| 17/26/17 | $0.1200 | 0.00% | 70,500 |
| 14/26/14 | $0.1200 | 0.00% | 17,000 |
| 13/26/13 | $0.1200 | 0.00% | 14,000 |
Annual profits - Rate of surprise
- Stock Market
- Stocks
- VM Stock
- VYYRF Stock
Select your edition
All financial news and data tailored to specific country editions
















